Member Exclusive News Drug approvals

New approval for gilteritinib as a monotherapy by European Commission

The European Commission has approved Astellas' XOSPATA™ (gilteritinib) as a monotherapy for relapsed or refractory acute myeloid leukemia patients with a FLT3 mutation.

Go to the profile of Georgi Makin
Oct 29, 2019

Please sign in or register for FREE

No comments yet.